Key facts
- Simianti Yaowu’s last known valuation is $7.5M (Dec 2022).
- It has raised $1.4M; the latest was Early Stage VC in Apr 2025.
- Notable investors include Value Capital, Suzhou Innovation Investment Group, Huaxi Securities Investment, Neijiang Technology Development.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Simianti Yaowu
- ·The full record, as it builds
Funding rounds
No funding rounds for Simianti Yaowu are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Simianti Yaowu
Developer and manufacturer of new small molecule drugs intended for the treatment of super-resistant bacteria and malignant tumors. The company has built an advanced technology platform for the development of new drugs against drug-resistant bacteria and a technology platform for the development of new drugs against drug-resistant tumors, providing innovative drug solutions for medical users and patients.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2021
- Website
- cdsimianti.com/
- Ownership
- Privately Held (backing)
Simianti Yaowu doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Simianti Yaowu shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Simianti Yaowu in its N-PORT filings yet. We sweep new filings monthly.